11th National Volume‑Based Procurement Launches, 55 Drugs Cut Prices to Benefit Patients
On May 25, 2026, the 11th National Centralized Drug Procurement results were fully implemented across public hospitals nationwide, covering 55 […]
Drug Updates
Japan Approves World’s First Esophageal Cancer Viral Therapy TeroMira, Ushering in Oncolytic Virus Era
On May 22, 2026, the Japanese MHLW expert committee formally approved TeroMira, developed by Oncolys Biopharma, for esophageal cancer, making
AstraZeneca’s Tezepelumab Approved in China for Severe Asthma and CRSwNP
On March 27, 2026, AstraZeneca announced tezepelumab injection (Tezspire®) received full NMPA approval in China for maintenance treatment of severe
Hengrui’s Bispecific Fusion Protein Relafusp Alfa Approved, Setting New First‑Line Standard for Gastric Cancer
In April 2026, relafusp alfa injection (Aizeli), a Class 1 innovative drug independently developed by Hengrui Medicine, was approved by
First‑Ever Chronic Hepatitis D Drug Hepcludex Approved in the U.S., Ending 40‑Year Gap
On May 22, 2026, the U.S. FDA granted accelerated approval to Gilead Sciences’ Hepcludex (bulevirtide) for chronic hepatitis D (HDV)
China’s 4th‑Generation BTK Inhibitor Lobrutinib Approved to Overcome Lymphoma Resistance
In early June 2026, the China NMPA granted conditional approval for lobrutinib tablets (LuKeda®) in adult patients with relapsed or
Key New Drug Approvals & Clinical Breakthroughs (June 2026)
Early June 2026 has witnessed a flurry of global approvals and clinical data releases, with multiple practice-changing advances. Below is
Global Drug Updates & Innovation Trends in H1 2026
Since the beginning of 2026, the global pharmaceutical industry has accelerated across drug R&D, clinical breakthroughs, regulatory approvals and technological